You are here

Finerenone: a new approach to kidney protection in patients with type 2 diabetes

Friday, 1 October 2021, 11:15 – 12:45, Rome Hall

Chair: A. Solini, IT

R.A. DeFronzo, US: New directions in kidney care in diabetes: targeting mineralocorticoid receptor overactivation with finerenone

G.L. Bakris, US: FIDELIO-DKD: cardiorenal outcomes in people with high-risk CKD and type 2 diabetes

L.M. Ruilope, ES: FIGARO-DKD: cardiorenal outcomes across the broad spectrum of CKD and type 2 diabetes

J.B. McGill, US: Navigating the data for key subgroup

A.L. Birkenfeld, DE: Maintaining the course: safety considerations for optimising patient outcomes

R. Agarwal, US: Setting the route for CKD and type 2 diabetes care: clinical consequences of the FIDELIO-DKD and FIGARO-DKD data

P.-H. Groop, FI: Commentary followed by Q&A